Treatment Outcomes in Black Patients with mHSPC: New Data and Insights

A panelist discusses how Black men have a 67% higher incidence of prostate cancer and more than 2-fold higher risk of mortality compared with members of other races and ethnicities.

A panelist discusses how the differences in prostate cancer among Black men are multifactorial, including biological differences in risk alleles, social determinants of health, and limited access to care and clinical trials.

Explore the critical underrepresentation of black men in metastatic hormone sensitive prostate cancer trials and its implications for treatment outcomes.

Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.